290 related articles for article (PubMed ID: 22759382)
1. Pathway-based classification of cancer subtypes.
Kim S; Kon M; DeLisi C
Biol Direct; 2012 Jul; 7():21. PubMed ID: 22759382
[TBL] [Abstract][Full Text] [Related]
2. Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis.
Schwede M; Spentzos D; Bentink S; Hofmann O; Haibe-Kains B; Harrington D; Quackenbush J; Culhane AC
PLoS One; 2013; 8(3):e57799. PubMed ID: 23536770
[TBL] [Abstract][Full Text] [Related]
3. Identification of metastasis and prognosis-associated genes for serous ovarian cancer.
Yang Y; Qi S; Shi C; Han X; Yu J; Zhang L; Qin S; Gao Y
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510146
[TBL] [Abstract][Full Text] [Related]
4. Identification of an energy metabolism‑related gene signature in ovarian cancer prognosis.
Wang L; Li X
Oncol Rep; 2020 Jun; 43(6):1755-1770. PubMed ID: 32186777
[TBL] [Abstract][Full Text] [Related]
5. A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer.
Meyniel JP; Cottu PH; Decraene C; Stern MH; Couturier J; Lebigot I; Nicolas A; Weber N; Fourchotte V; Alran S; Rapinat A; Gentien D; Roman-Roman S; Mignot L; Sastre-Garau X
BMC Cancer; 2010 May; 10():222. PubMed ID: 20492709
[TBL] [Abstract][Full Text] [Related]
6. A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
Rudolph M; Sizemore ST; Lu Y; Teng KY; Basree MM; Reinbolt R; Timmers CD; Leone G; Ostrowski MC; Majumder S; Ramaswamy B
Breast Cancer Res Treat; 2018 Jun; 169(3):457-467. PubMed ID: 29464534
[TBL] [Abstract][Full Text] [Related]
7. Robust edge-based biomarker discovery improves prediction of breast cancer metastasis.
Adnan N; Lei C; Ruan J
BMC Bioinformatics; 2020 Sep; 21(Suppl 14):359. PubMed ID: 32998692
[TBL] [Abstract][Full Text] [Related]
8. OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.
Madden SF; Clarke C; Stordal B; Carey MS; Broaddus R; Gallagher WM; Crown J; Mills GB; Hennessy BT
Mol Cancer; 2014 Oct; 13():241. PubMed ID: 25344116
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer.
Shen S; Wang G; Zhang R; Zhao Y; Yu H; Wei Y; Chen F
EBioMedicine; 2019 Feb; 40():318-326. PubMed ID: 30594555
[TBL] [Abstract][Full Text] [Related]
10. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
Zhao Q; Fan C
BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
[TBL] [Abstract][Full Text] [Related]
11. Downregulated Long Noncoding RNA DGCR5 Acts as a New Promising Biomarker for the Diagnosis and Prognosis of Ovarian Cancer.
Chen H; Tian X; Luan Y; Lu H
Technol Cancer Res Treat; 2019; 18():1533033819896809. PubMed ID: 31868103
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Prognostic Utility of the Diverse Molecular Data among lncRNA, DNA Methylation, microRNA, and mRNA across Five Human Cancers.
Xu L; Fengji L; Changning L; Liangcai Z; Yinghui L; Yu L; Shanguang C; Jianghui X
PLoS One; 2015; 10(11):e0142433. PubMed ID: 26606135
[TBL] [Abstract][Full Text] [Related]
13. Four genes relevant to pathological grade and prognosis in ovarian cancer.
Pan X; Chen Y; Gao S
Cancer Biomark; 2020; 29(2):169-178. PubMed ID: 32444534
[TBL] [Abstract][Full Text] [Related]
14. Identification of Gene-Expression Signatures and Protein Markers for Breast Cancer Grading and Staging.
Yao F; Zhang C; Du W; Liu C; Xu Y
PLoS One; 2015; 10(9):e0138213. PubMed ID: 26375396
[TBL] [Abstract][Full Text] [Related]
15. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
Liu R; Guo CX; Zhou HH
Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
[TBL] [Abstract][Full Text] [Related]
16. A Steiner tree-based method for biomarker discovery and classification in breast cancer metastasis.
Jahid MJ; Ruan J
BMC Genomics; 2012; 13 Suppl 6(Suppl 6):S8. PubMed ID: 23134806
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma.
Canevari RA; Marchi FA; Domingues MA; de Andrade VP; Caldeira JR; Verjovski-Almeida S; Rogatto SR; Reis EM
Tumour Biol; 2016 Oct; 37(10):13855-13870. PubMed ID: 27485113
[TBL] [Abstract][Full Text] [Related]
18. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
Hachim IY; Shams A; Lebrun JJ; Ali S
Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
[TBL] [Abstract][Full Text] [Related]
19. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.
Ghayad SE; Vendrell JA; Bieche I; Spyratos F; Dumontet C; Treilleux I; Lidereau R; Cohen PA
J Mol Endocrinol; 2009 Feb; 42(2):87-103. PubMed ID: 18984771
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation.
Smith DD; Saetrom P; Snøve O; Lundberg C; Rivas GE; Glackin C; Larson GP
BMC Bioinformatics; 2008 Jan; 9():63. PubMed ID: 18226260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
